Lackey Melinda 4

What Happened

• Melinda Lackey, General Counsel & SVP of Legal at Valion Bio (VBIO), was granted a derivative equity award covering 45,000 shares on 2026-05-01. The reported acquisition price/strike is $0.00, so the immediate reported cash value is $0. This is a compensation grant (award), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-05-01; Form filed: 2026-05-04.
• Shares/units granted: 45,000 (derivative award); reported price/strike: $0.00.
• Shares owned after transaction: Not reported in the Form 4 provided.
• Footnote: Vesting is 25% at the first anniversary of the grant, then the remaining 75% in 12 equal quarterly installments (rounded down), so the award is fully vested on the fourth anniversary.
• Filing timeliness: No late-filing flag indicated in the supplied details.

Context

• This is an equity compensation grant (derivative award) that vests over four years; it does not represent an immediate open-market purchase or sale. Such grants are common for employee compensation and do not by themselves indicate a personal buy or sell decision.